Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Study to assess the effects of tegaserod added to PPI therapy in the resolution of heartburn and regurgitation in patients with incomplete relief from PPIs .

Inclusion Criteria:

• Heartburn for at least 3 days in the week prior to screening
• Regurgitation for at least 3 days in the week prior to screening
• Stable dose PPI therapy > 4 weeks
• Incomplete relief on daily PPI therapy > 4 weeks

Exclusion Criteria:

• Evidence of structural abnormality of the gastrointestinal tract or disease/conditions
• Previous gastrointestinal surgery that may influence esophageal motor function
• Evidence of cathartic colon or a history of laxative use

Other protocol-defined inclusion/exclusion criteria may apply.